Complete Surgical Resection Is Curative for Children With Hepatoblastoma With Pure Fetal Histology: A Report From the Children's Oncology Group

Division of Hematology-Oncology, Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.
Journal of Clinical Oncology (Impact Factor: 18.43). 08/2011; 29(24):3301-6. DOI: 10.1200/JCO.2010.29.3837
Source: PubMed


Children with pure fetal histology (PFH) hepatoblastoma treated with complete surgical resection and minimal adjuvant therapy have been shown to have excellent outcomes when compared with other patients with hepatoblastoma. We prospectively studied the safety and efficacy of reducing therapy in all children with stage I PFH enrolled onto two consecutive studies.
From August 1989 to December 1992, 9 children with stage I PFH were treated on the Intergroup Hepatoblastoma study INT-0098 and were nonrandomly assigned to receive chemotherapy after surgical resection with single-agent bolus doxorubicin for 3 consecutive days. From March 1999 to November 2006, 16 children with stage I PFH enrolled onto Children's Oncology Group Study P9645 were treated with observation after resection. Central confirmation of the histologic diagnosis by a study group pathologist was mandated. The extent of liver disease was assigned retrospectively according to the pretreatment extent of disease (PRETEXT) system and is designated "retro-PRETEXT" to clarify the retrospective group assignment.
Five-year event-free and overall survival for the 9 patients treated on INT-0098 were 100%. All 16 patients enrolled onto the P9645 study were alive and free of disease at the time of last contact, with a median follow-up of 4.9 years. Retro-PRETEXT for the 21 patients with available data revealed seven patients with stage I disease, 10 patients with stage II disease, and four patients with stage III disease.
Children with completely resected PFH hepatoblastoma can achieve long-term survival without additional chemotherapy. When feasible, surgical resection of hepatoblastoma at diagnosis, without chemotherapy, can identify children for whom no additional therapy is necessary.

Download full-text


Available from: Joel E. Haas,
50 Reads
  • Source
    • "Non-anatomic, or wedge resections are not recommended [16]. In the case of pure fetal HB a primary resection may be attempted to avoid toxic chemotherapy [17]. To date this approach has not been accepted by SIOPEL and is rarely done in Europe. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Beckwith–Wiedemann syndrome (BWS) predisposes to embryonic tumors. The concomitant presence of pathologically different tumors requires patient-specific surgical care. We report a case of simultaneous occurrence of a hepatoblastoma (HB) and an infantile hepatic hemangioma (IHH). A 4-month-old girl with BWS presented with two liver masses (one in segment VI/V and the other in segment VII). Biopsy of the larger lesion confirmed the diagnosis of HB. Standard chemotherapy was started and a right hepatectomy was planned. The two masses reacted differently to chemotherapy, with a marked decrease in the size of the larger tumor, and no change in the size of the smaller one. Thus, after four chemotherapy cycles, enucleation of the smaller of the two masses was performed and intraoperative examination of the specimen revealed the presence of an IHH. Segmentectomy of the second, larger tumor was then performed, instead of the originally planned right hepatectomy. The presence of both HB and IHH in children with BWS is rare. Early recognition of the two different tumors allows for patient-specific surgical care, with resection of less liver tissue. This is important in children with BWS given the persistent lifelong risk for additional liver tumors requiring liver resections.
    Journal of Pediatric Surgery Case Reports 04/2013; 1(4):53–55. DOI:10.1016/j.epsc.2013.03.011
  • [Show abstract] [Hide abstract]
    ABSTRACT: Tumours and pseudotumours of the liver are a heterogeneous group of neoplasm including 60% of malignant tumours. Malignant liver tumours account for less than 2% of the lesions in children and vary considerably in incidence throughout the paediatric age range, with hepatoblastoma, rhabdoid tumour of the liver, hemangioendothelioma, biliary tract rhabdomysosarcoma and mesenchymal hamartoma in the first two years of life and hepatocellular carcinoma, focal nodular hyperplasia, and undifferentiated sarcoma in older children and adolescents. Treatment of malignant epithelial tumours is based on the surgical resection of the tumour associated with pre- and postoperative chemotherapy including cisplatinum. Modalities of the treatment are adapted to risk factors. Survival rates at three years are over 80% for localised hepatoblastoma whereas they are less than 30% in hepatocellular carcinomas. The role of targeted therapies still has to be defined.
    Bulletin du cancer 02/2012; 99(2):219-28. DOI:10.1684/bdc.2011.1539 · 0.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hepatoblastoma is the most common liver tumor of early childhood. According to recent studies its incidence seems to be increasing in North America and Europe. Since new histological variants have been described recently the formerly clear-cut distinction of hepatoblastoma and hepatocellular carcinoma may not be valid anymore and a new histological classification will be inaugurated by an international working group. Recent research identified prognostically relevant gene signatures as well as potential molecular targets for therapy of hepatoblastoma. The multicentric study groups in the USA, Europe and Japan recommend cisplatin based chemotherapy for neoadjuvant and adjuvant treatment. However, their risk stratification systems and general treatment strategies differ substantially. Therefore the four groups agreed to pool their patients' data for an analysis of prognostic criteria which can be used for defining common risk groups. While 90% of standard risk and 65% of high risk hepatoblastomas can be cured, the still dismal outcome of multifocal disseminated and metastasising tumors warrants the investigation of new cytotoxic drugs and substances against specific molecular targets.
    Seminars in Pediatric Surgery 02/2012; 21(1):21-30. DOI:10.1053/j.sempedsurg.2011.10.011 · 2.22 Impact Factor
Show more